Literature DB >> 15109582

Dementia with Lewy bodies and Parkinson's disease.

I G McKeith1, U P Mosimann.   

Abstract

Lewy bodies (LB) in the central nervous system are associated with several different clinical syndromes including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Long term follow up of PD patients finds up to 78% eventually develop dementia, most of these patients exhibiting fluctuating cognition and visual hallucinations similar to DLB and with extensive cortical LB at autopsy. alpha-Synuclein positive, neuritic pathology, in the putamen of DLB and Parkinson's disease dementia (PDD), may contribute to postural-instability gait difficulty, parkinsonism, diminished levodopa responsiveness and increased neuroleptic sensitivity. Cognitive and neuropsychiatric symptoms improve with cholinesterase inhibitor treatment in both patient groups. DLB and PDD should be seen as different points on a spectrum of LB disease. Distinguishing them as separate disorders may be useful in clinical practice, but may be of limited value in terms of investigating and treating the underlying neurobiology.

Entities:  

Mesh:

Year:  2004        PMID: 15109582     DOI: 10.1016/j.parkreldis.2003.12.005

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  19 in total

1.  Neuroprotective upregulation of endogenous α-synuclein precedes ubiquitination in cultured dopaminergic neurons.

Authors:  R E J Musgrove; A E King; T C Dickson
Journal:  Neurotox Res       Date:  2010-07-09       Impact factor: 3.911

Review 2.  Neuropathological investigation of dementia: a guide for neurologists.

Authors:  S Love
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

3.  Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.

Authors:  B Ravina; M Putt; A Siderowf; J T Farrar; M Gillespie; A Crawley; H H Fernandez; M M Trieschmann; S Reichwein; T Simuni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

4.  Differential nigral expression of bcl-2 protein family in the pure and common forms of Dementia with Lewy bodies: relevance for dopaminergic neuronal vulnerability.

Authors:  M Saldaña; E Aguilar; M Bonastre; C Marin
Journal:  J Neural Transm (Vienna)       Date:  2007-07-04       Impact factor: 3.575

5.  Dementia with Lewy Bodies versus Alzheimer's Disease and Parkinson's Disease Dementia: A Comparison of Cognitive Profiles.

Authors:  Kyung Won Park; Hyun Sook Kim; Sang-Myung Cheon; Jae-Kwan Cha; Sang-Ho Kim; Jae Woo Kim
Journal:  J Clin Neurol       Date:  2011-03-31       Impact factor: 3.077

Review 6.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

7.  Parkinson disease with and without Dementia: A prevalence study and future projections.

Authors:  Rodolfo Savica; Brandon R Grossardt; Walter A Rocca; James H Bower
Journal:  Mov Disord       Date:  2018-01-22       Impact factor: 10.338

8.  Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole.

Authors:  Giulia Ferrari-Toninelli; Giuseppina Maccarinelli; Daniela Uberti; Erich Buerger; Maurizio Memo
Journal:  BMC Pharmacol       Date:  2010-02-05

9.  The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies.

Authors:  Kay Seidel; Josefine Mahlke; Sonny Siswanto; Reijko Krüger; Helmut Heinsen; Georg Auburger; Mohamed Bouzrou; Lea T Grinberg; Helmut Wicht; Horst-Werner Korf; Wilfred den Dunnen; Udo Rüb
Journal:  Brain Pathol       Date:  2014-09-12       Impact factor: 6.508

Review 10.  Dopaminergic agonists: possible neurorescue drugs endowed with independent and synergistic multisites of action.

Authors:  Daniela Uberti; Irene Bianchi; Luca Olivari; Giulia Ferrari-Toninelli; Sara A Bonini; Maurizio Memo
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.